Gynecologic Oncology Research Group






Click on the blue text below for more information

Principal Investigator


Doris M. Benbrook, PhD

OK-1 (SHetA2) Drug Facebook Page





Collaborating Faculty


Bethany Hannafon, PhD, Assistant Professor of Research

Exosome and miRNA Breast Cancer Biomarkers


Vishal Chandra, PhD, Assistant Professor or Research

Endometrial Cancer Prevention and Treatment


Satish Ramraj, PhD, Postdoctoral Fellow

Prevention of Fallopian Tube Carcinogenesis to Ovarian Cancer






Postdoctoral Fellows

Rajani Rai, PhD

Prevention of Tobacco Carcinogenesis


Sugantha Priya Elayapillai, PhD

Repurposing Mebendazole for Ovarian Cancer
















Amy Bosley, BA,

Pathology Department

Combination Drug Therapy for Cervical Cancer

Zitha Isingizwe, BS,

Pharmaceutical Sciences Department

How to prevent platelet promotion of ovarian cancer





Current Research Projects:


How does ovarian cancer develop from the fallopian tube and how can it be prevented?


Recent Publications:

Benbrook, D. M., Janakiram, N. B., Chandra, V.*, Pathurib, G., Madk, V., Stratton, N. C., Masamha, C. P, Farnsworth, C. N., Garcia-Contreras, L., Hatipoglu, M. K., Lightfoot, S., Rao, C. V. (2018). Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational New Drugs, 36(4), 561-570. PMID: 29273857. DOI: 10.1007/s10637-017-0550-0

Ramraj, S. K., Smith, K. M., Janakiram, N. B., Toal, C., Raman, A., Benbrook, D. M. (2018). Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue & cell, 52, 57-64. PMID: 29857829. DOI: 10.1016/j.tice.2018.04.001


Current Funding:


Benbrook, D. M. (Principal Investigator), 40% Effort, Rao, C. (Co-Investigator), Janakiram, N. (Co-Investigator), Garcia-Contreras, L. (Co-Investigator), Woo, S. (Co-Investigator), Zuna, R. (Co-Investigator), Crouse, E. (Co-Investigator),

Ovarian Cancer Chemoprevention

Peer-reviewed Nationally-funded Research Grant, Sponsored by National Cancer Institute, Federal  Grant/Contract Number: R01 CA196200/C31042101
Current Funding (Total Cost per Year): $503,992

Total Direct Costs Per Year: $340,535
July 1, 2015 - June 30, 2020


Benbrook, D. M. (Principal Investigator)

 "cGMP NSC 721689 Production for IRB-approved and NCI-funded Clinical Trials,"

Sponsored by NCI PREVENT, Federal
Grant/Contract Number: 721689
February 10, 2015 - Present


How do HPV and tobacco cause cervical cancer and how can it be prevented and treated?

Current Funding:


Benbrook, D. M. (Principal Investigator), 30% Effort, Rao, C. (Co-Principal Investigator), Zuna, R. (Co-Investigator), Garcia-Contreras, L. (Co-Principal Investigator), Woo, S. (Co-Principal Investigator), Zhao, D. (Co-Investigator), Frumovitz, M. (Co-Principal Investigator), Coleman, R. (Co-Principal Investigator),

Targeting HPV Consequences in a Cervical Cancer Clinical Trial Peer-reviewed, federally-funded research grant, Sponsored by NIH/NCI, Federal Grant/Contract Number: R01 CA200126/C3111201
Current Funding (Total Cost per Year): $595,072
Total Direct Costs: $425,303.00

June 1, 2016 - May 31, 2022


How do estrogen and obesity cause endometrial cancer and how can it be prevented and treated?

Recent Publications:

Chandra, V., Kim, J. J., Benbrook, D. M., Dwivedi, A., Rai, R.#, Gyeongbuk, G. (2016). Therapeutic options for management of endometrial hyperplasia: An update. J Gynecol Oncol, 27(1). PMID: 26463434. DOI: 10.3802/jgo.2016.27.e8


Current Funding:

Benbrook, D. M. (Project Director), Chandra, V. (Co-Project Director), Rai, R. (Co-Project Director), Rao, C. (Principal Investigator), Chemoprevention of Endometrial Hyperplasia and Its Transition to Endometrial Cancer with NSC 721689

Sponsored by NCI PREVENT Program, Federal Direct Total Costs $713,988
June 16, 2017 - June 14, 2019


Can glycoprotein expression in tumor biopsies predict cervical cancer lymph node metastases?

Clinical Trial:

Benbrook, D. M. (Study Co-Chair), Gold, M. A. (Study Chair), Cummings, R. (Study Co-Chair), Rodgers, W. (Study Co-Chair), Comparison of Glycoprotein Expression and T-Synthase Function in Primary versus Metastatic Tumors

Sponsored by Gynecologic Oncology Group, Foundation Grant/Contract Number: GOG - 0221
April 13, 2007 - August 24, 2017